Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood

Trial Profile

Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2018

At a glance

  • Drugs INB 03 (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Renal cancer
  • Focus Adverse reactions; Biomarker; First in man; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2018 Anticipated date last participant enrolled is 1/4/2019
    • 01 Aug 2018 Planned End Date changed from 17 May 2019 to 4 Oct 2019.
    • 01 Aug 2018 Planned initiation date (Estimated date of first participant enrollment) changed from 4 Jun 2018 to 6 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top